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Abstract
Promoting remyelination is recognized as a novel strategy to foster repair in neurodegenerative
demyelinating diseases, such as multiple sclerosis. In this respect, the receptor GPR17, recently
emerged as a new target for remyelination, is expressed by early oligodendrocyte precursors
(OPCs) and after a certain differentiation stage it has to be downregulated to allow progression to
mature myelinating oligodendrocytes. Here, we took advantage of the first inducible GPR17
reporter mouse line (GPR17-iCreERT2xCAG-eGFP mice) allowing to follow the final fate of
GPR171 cells by tamoxifen-induced GFP-labeling to unveil the destiny of these cells in two demy-
elination models: experimental autoimmune encephalomyelitis (EAE), characterized by marked
immune cell activation and inflammation, and cuprizone induced demyelination, where myelin dys-
function is achieved by a toxic insult. In both models, demyelination induced a strong increase of
fluorescent GFP1 cells at damaged areas. However, only in the cuprizone model reacting GFP1
cells terminally differentiated to mature oligodendrocytes, thus contributing to remyelination. In
EAE, GFP1 cells were blocked at immature stages and never became myelinating oligodendro-
cytes. We suggest these strikingly distinct fates be due to different permissiveness of the local
CNS environment. Based on previously reported GPR17 activation by emergency signals (e.g.,
Stromal Derived Factor-1), we propose that a marked inflammatory milieu, such as that reproduced
in EAE, induces GPR17 overactivation resulting in impaired downregulation, untimely and pro-
longed permanence in OPCs, leading, in turn, to differentiation blockade. Combined treatments
with remyelinating agents and anti-inflammatory drugs may represent new potential adequate
strategies to halt neurodegeneration and foster recovery.
K E YWORD S
animal models, differentiation, G protein-coupled receptor, multiple sclerosis, oligodendrocyte pre-
cursor cells
*Giusy T. Coppolino and Davide Marangon contributed equally to the present study.
†Davide Lecca and Maria P. Abbracchio should be considered joint senior author.
.......................................................................................................................................................................................
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, pro-
vided the original work is properly cited.
VC 2018 The Authors GLIA Published by Wiley Periodicals, Inc.
Glia. 2018;1–13. wileyonlinelibrary.com/journal/glia | 1
Received: 22 September 2017 | Revised: 13 January 2018 | Accepted: 29 January 2018
DOI: 10.1002/glia.23305
1 | INTRODUCTION
Oligodendroglial precursor cells (OPCs), also known as NG2 cells due
to their expression of the proteoglycan NG2, are known to proliferate
and participate to remyelination during multiple sclerosis. However,
while disease progresses, this process becomes progressively less effi-
cient, eventually resulting in blockade of oligodendroglial differentiation
and impaired myelin repair (Podbielska, Banik, Kurowska, & Hogan,
2013). This, in turn, leads not only to overt neurological disturbances
due to interruption of impulse transmission, but also to axonal damage
and neurodegeneration followed by progression of the remitting-
relapsing to the progressive chronic form of the disease. The reasons
responsible for the progressive loss of patients’ remyelinating abilities
are still under study. Thus promoting myelination via a specific action
on key molecules involved in OPC maturation has been increasingly
recognized as a promising strategy to foster endogenous remyelination,
especially in the progressive forms (Rovaris et al., 2006).
In this respect, the G protein-coupled receptor GPR17 has recently
emerged as a key timer of oligodendrogliogenesis. In the intact brain
and spinal cord, GPR17 is specifically expressed by a subset of early
bipolar NG2 positive (GPR171-NG21) OPCs, accompanies OPC matu-
ration up to immature/pre-oligodendrocytes and is then downregulated
before terminal maturation (Lecca et al., 2008; Ceruti et al., 2009). Any
alterations in this precise expression pattern result in myelination
defects (Chen et al., 2009; Fumagalli et al., 2011; Fumagalli et al.,
2015). Pathologically increased levels of GPR17 have been found after
focal lysolecithin induced demyelination (Boda et al., 2011), following
brain ischemia in rodents subjected to middle cerebral artery occlusion
(MCAO) (Ciana et al., 2006; Lecca et al., 2008) and after traumatic brain
injury in both rodents (Boda et al., 2011) and human subjects (Franke
et al., 2013). In initial studies, the mRNA for GPR17 was also found to
be increased in the spinal cord of mice with experimental autoimmune
encephalomyelitis (EAE) and in the spinal lesions of multiple sclerosis
patients (Chen et al., 2009). The exact significance of persistent GPR17
overexpression in vivo under demyelinating conditions is still unknown.
Our in vitro data suggest that GPR17 aberrant overexpression in OPCs
leads to impaired downregulation at late differentiation stages and
blockade of cells at immature stages, thus impairing remyelination
(Fumagalli, Lecca, & Abbracchio, 2016). Initial data also suggest that
GPR17 overexpression may be due, at least in part, to inflammatory
cytokines and chemokines like the stromal derived factor 1 (SDF1),
that accumulate at the sites of demyelinating inflamed lesions (Cal-
deron et al., 2006) and can indeed specifically interact with this recep-
tor (Parravicini et al., 2016). However, a detailed study on GPR17
dysfunction in in vivo conditions associated to demyelination and
inflammation is still missing, nor is known whether changes in the pool
of GPR171 cells contribute to, or contrast, lesion repair.
Here, to shed light on this issue, we used two rodent demyelination
models: the autoimmune experimental encephalomyelitis (EAE) model,
the most studied animal model of human multiple sclerosis over the
past decades, and the cuprizone-induced model, that bypasses the
autoimmune component and is more adequate to study the timing of
demyelination and remyelination phases (Denic et al., 2011). To detail
the final fate of the GPR17-expressing cells and to unveil whether they
indeed become functionally mature myelinating oligodendrocytes, we
took advantage of the first inducible fluorescent GPR17 reporter mouse
line for fate mapping studies (GPR17-iCreERT2xCAG-eGFP mice),
where, upon tamoxifen treatment, all GPR17-expressing cells at that
specific moment become permanently fluorescent, and can be traced
throughout life (Vigano et al., 2016). Since, as already mentioned,
GPR17 is only transiently expressed by OPCs and is no longer present
in mature myelinating oligodendrocytes (Lecca et al., 2008; Fumagalli
et al., 2011; Fumagalli et al., 2015) this transgenic mouse line represents
the only possible means to follow in vivo the final destiny of the
GPR171 pool of OPCs, even after cells have physiologically downregu-
lated the receptor along their differentiation pathway.
We show that, in both models of demyelination, the pool of
GPR171 OPCs rapidly responds by increasing the number of GFP1
cells accumulating at demyelinated lesions, but that only in the cupri-
zone model these activated cells can successfully proceed to terminal
differentiation and start expressing myelin proteins. Instead, in EAE,
GFP1 cells are blocked at immature stages and do not express mature
myelin markers. We postulate that the inflammatory environment
could be responsible for the lack of GPR17 down-regulation and the
subsequent remyelination failure.
2 | MATERIALS AND METHODS
2.1 | Animal care
For all animal studies, international (European law Dir. 2010/63/UE) and
national (Italian law DL n. 26, 4th March 2014) guidelines for the care
and use of animals were followed. All the procedures were approved by
the Italian Ministry of Health (authorization 473–2015PR to MPA).
Mice were housed in groups of 4, under a 12-hr light/12-hr dark cycle
at 218C, with food and water ad libitum. In selected experiments we used
wild-type mice (purchased from Charles River, Calco, Italy) or adult animals
from the GPR17-iCreERT2xCAG-eGFP mouse line. In this case mice were
maintained and bred at our local facilities. Offspring were ear punched
and genotyped using PCR as previously reported (Vigano et al., 2016). The
body weight of the mice was monitored during all experiments.
2.2 | Experimental design
The experiments were designed in compliance with the ARRIVE guide-
lines. Control groups were included in all experiments, randomizing the
procedures and applying double-blinded analysis when possible. Sam-
ple size was calculated with G-Power, considering a significant level of
.05. Based on our preliminary results, to reach a power between 0.80
and 0.90, we needed a minimum of n 5 4 (immunohistochemistry, RT-
PCR), depending on the specific experimental conditions. This number
is in line to those generally employed in the field.
2.3 | EAE induction
EAE was induced in 8-week-old female wild-type C57Bl/6 mice
(Charles River) by subcutaneous immunization in the flanks and in the
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tail base with 200 lg of myelin oligodendrocyte glycoprotein
(MOG35–55, Espikem, Florence, Italy) per mouse in incomplete
Freund’s adjuvant (IFA, Sigma-Aldrich, Milan, Italy) supplemented with
8 mg/ml of Mycobacterium tuberculosis (strain H37Ra, BD Difco,
Milan, Italy). The immunized mice received intravenously 500 ng of per-
tussis toxin (PTX, Duotech, Milan, Italy) the day of the immunization
and 48 hr later. Animals were daily weighted and scored for clinical
symptoms of EAE according the following scale (clinical score, CS):
0 5 healthy, 1 5 flaccid tail, 2 5 ataxia and/or paresis of hindlimbs,
3 5 paralysis of hindlimbs and/or paresis of forelimbs,
4 5 tetraparalysis, 5 5 moribund or death. Non-EAE age-matched con-
trols received PTX injections, as well as the initial injections of emulsion
but without the encephalitogen, to ensure that observed effects are
due to EAE and not to a non-specific reaction to the ancillary compo-
nents that are used to facilitate disease induction. The animals were
sacrificed 21 days post immunization (dpi) for histological and real-time
PCR analysis. For the analysis only animals with CS > 1.5 were consid-
ered. The use of female mice was based on the documented higher
response to MOG immunization. Moreover, higher aggressiveness of
C57BL/6 male mice was reported to increase stress, with production
of corticosteroids that can inhibit EAE development (Miller & Karpus
2007). Also for this reason, the use of female mice is usually preferred.
2.4 | Cuprizone-induced demyelination
Eight-week-old age male C57BL/6 wild-type mice (Charles River) were
fed with 0.2% (weight/weight) cuprizone-supplemented diet (Sigma-
Aldrich) ad libitum for 5 weeks and were then switched to normal diet for
further 3 weeks to allow spontaneous remyelination (Gudi, Gingele,
Skripuletz, & Stangel, 2014). Immunohistochemistry and qRT-PCR analy-
sis were performed at the beginning of the treatment (W0) and after 1, 3,
5, and 7 weeks. Although the course of de- and remyelination is similar
between genders in C57BL/6 mice, the use of male mice is more well-
documented in the literature (Taylor, Gilmore, Ting, & Matsushima, 2010).
2.5 | Tamoxifen induction
Tamoxifen (40 mg/ml; Sigma-Aldrich) was diluted in ethanol (final con-
centration 10%) and corn oil. Every other day mice received for three
times 10 mg of tamoxifen suspension by oral gavaging (for a total of
30 mg) 2 weeks before EAE induction and were sacrificed 21 dpi for
histological and real-time PCR analysis. In case of cuprizone-induced
demyelination, GFP expression with tamoxifen was induced at week 3,
as described above.
2.6 | Histological analysis, immunofluorescence
and cell counts
Mice were anesthetized with ketamine (100 mg/kg)/xylazine (10 mg/kg)
and perfused transcardially with saline-0,1 M EDTA (Sigma Aldrich) fol-
lowed by 4% neutral buffered formalin (Sigma Aldrich) in deionized
water. Spinal cords were collected and post-fixed for 1 hr in the same
solution at 48C, cryoprotected in 30% sucrose for 24 hr (until the tissue
sinks to the bottom of the tube), embedded in OCT and then frozen at
2808C. Spinal cords were cut transversally into 20 mm-thick sections
with a cryostat and processed for immunofluorescence.
Slides were incubated for 45 min at room temperature with a
blocking solution composed by 10% normal goat serum and 0.1% triton
X-100 in 13 phosphate buffered saline (PBS).
Then, the sections were incubated with primary antibodies over-
night at 48C in 13 PBS with 5% goat normal serum and 0.1% Triton X-
100. The following primary antibodies were used: rabbit polyclonal
anti-GPR17 (1:2,500, custom antibody produced by PRIMM, Milan,
Italy), anti-NG2 (1:2,000, Millipore, Milan, Italy), anti-OLIG2 (1:500,
Millipore), anti-IBA1 (1:500; Wako, Japan), anti-GSTp (1:300, MBL,
Woburn, USA), chicken polyclonal anti-GFP (1:1,400, Aves Labs, Tigard,
Oregon, USA), and mouse monoclonal anti-GFAP (1:500, Cell Signalling,
Danvers, USA), anti-CC1 (1:50, Millipore), anti-MAP2 (1:500, Immuno-
logical sciences, Rome, Italy), anti-NEUN (1:100, Millipore).
Following primary antibody incubation, the sections were washed
and incubated with the appropriate biotinylated secondary antibody
(Vector Labs, Burlingame, USA), and/or with Alexa 405, 488, or 568
conjugated secondary antibody or streptavidin (Invitrogen, Molecular
Probes, Monza, Italy) for 1 hr at room temperature. Hoechst 33528
was used to visualize cell nuclei. After processing, sections were
mounted on microscope slides with fluorescent mounting medium
(Dako, Milan, Italy). GPR17 labeling was amplified with the high sensi-
tivity tyramide signal amplification kit (Perkin Elmer, Milan, Italy)
according to the manufacturer’s instruction.
After immunofluorescence, one section from each level (cervical,
thoracic, and lumbar- sacral) of the spinal cord was analyzed for each
animal. Seven arbitrary non-overlapping sample fields were counted
separately in white matter (WM) and six fields in gray matter (GM) of
every section at 403 magnification.
For the correlation analysis GFP1 cells were counted in 41 fasciculus
gracilis area of EAE mice in whole spinal cord (cervical, thoracic, and
lumbar-sacral levels). Fluoromyelin red stain (1:300 in 13 PBS; Thermo-
fisher Scientific, Milan, Italy) was used to selectively label myelin in this area.
Luxol fast blue staining was performed to mark myelin in the cor-
pus callosum of mice (Supporting Information Figure S1). In detail, sec-
tions were acclimatized at room temperature for 20 min and then
dehydrated by passing the slides through growing graded alcoholic sol-
utions (70, 90, 100% EtOH), 2 min each. Slides were then incubated
with Luxol Fast Blue solution (Sigma Aldrich; 1 mg/ml in 95% EtOH,
0.5% acetic acid) over-night at 568C. The next day, the excess stain
was rinsed off first with 95% EtOH and then with distilled water, 30 s
each. The differentiation step was performed first in lithium carbonate
solution and then in 70% EtOH, 30 s each, and finally slides were
rinsed in distilled water. Differentiation step was repeated till GM was
clear and WM sharply defined by the blue stain in control condition.
Hematoxylin (Sigma Aldrich) was used to counterstain sections. Slides
were mounted with DPX mountant for histology (Sigma Aldrich).
2.7 | In situ hybridization
Slides were dried at room temperature for 5 min. After one wash in 1X
PBS-DEPC, slides were post-fixed in 4% paraformaldehyde for 5 min,
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washed in 13 PBS-DEPC, washed for 10 min with 23 SSC and then
incubated in Tris-Glycine 0.1M (pH 7) for 20 min. Sections were perme-
abilized in protease K (20 lg/ml in 13 PBS) for 10 min at 378C. The activ-
ity of protease K was stopped by fixation in 4% paraformaldehyde for
5 min, followed by two 5-min washes in 13 PBS. Slides were incubated
in 0.25% acetic diaminobenanhydride (Sigma-Aldrich) with 0.1M trietha-
noloamine (pH 8.0; Sigma-Aldrich) for 10 min at room temperture, and
then washed in 23 SSC for 10 min. Digoxigenin-labeled cRNA (0.3 lg/
ml) of either antisense or sense probes were added to hybridization
buffer containing 50% formamide, 10% dextran sulphate, 13 Denhardt’s
solution, 43 SSC, 250 lg/ml salmon sperm, 10 mM DTT and 250 lg/ml
Escherichia coli tRNA. Hybridization was carried out for 16 hr at 558C in
hybridization oven. The sections were incubated in 23 SSC for 30 min at
528C, quickly washed twice in 0.23 SSC, and then cooled in 13 PBS at
room temperature. The following protocol was used to detect the hybrid-
ization signals. First, the sections were incubated in blocking buffer con-
taining 3% bovine serum albumin (Sigma-Aldrich) and 0.1% Triton X-100
in PBS at room temperature for 30 min, and then with anti-digoxigenin
sheep IgG Fab fragments conjugated to alkaline phosphatase (Roche,
Monza, Italy) diluted 1:500 in the blocking buffer o/n. Slides were
washed 3 times with 13 PBS, then in Buffer 1 (0.1M Tris-HCl, pH 7.5,
0.1M NaCl) and finally equilibrated in Buffer 2 (0.1M Tris-HCl, pH 9.5,
0.1M NaCl, 0.05MMgCl). Color development was obtained with 400 lg/
ml nitro blue tetrazolium, 200 lg/ml 5-bromo-4-chloro-3-indolyl phos-
phate and 100 lg/ml levamisole in buffer 2 in the dark at room temper-
ture for 10 min. The sections were rinsed in distilled water to stop color
development, and then dried by soaking the slides through growing
graded alcoholic solutions (50%, 75%, 95%, and 100%) and xylene for
10 min. Slides were mounted with DPX (Sigma-Aldrich).
Mouse GPR17 cDNA sequences (sense: 50 GATGAACGGTCTG-
GAGGCAGCC 30; antisense: 50 CTCACAGCTCGGATCGGGCAC 30)
were inserted in a pBlu2KSM-T vector (Clontech, USA). Digoxigenin-
labeled RNA probes were synthesized following the manufacturer’s
instructions (Roche, Monza, Italy).
2.8 | Total RNA extraction, retrotranscription and
gene expression analysis
Total RNA was extracted from cells or tissues using Trizol reagent (Life
Technologies, Monza, Italy). For gene expression analysis, cDNA syn-
thesis was performed starting from 800 ng of total RNA using Super-
Script II Reverse Transcriptase (Life Technologies). The expression of all
genes was analysed using Sybr-green reagents (Bio-rad, Milan, Italy)
and normalized to GAPDH expression using CFX96 real-time PCR sys-
tem (Bio-rad) following the manufacturer’s protocol. The Ct values
were elaborated with the comparative CT method (DDCT) which allows
the relative quantification of template comparing the expression levels
of the interested gene with the ones of the housekeeping gene.
2.9 | Statistical analysis
Data are presented as mean 6 SEM and analyzed with the GraphPad
Prism 6.0 software. For all comparisons between two groups with a
normal distribution, two-tailed unpaired Student t-test was performed.
For multiple comparison testing, one-way analysis of variance (ANOVA)
accompanied by Tukey’s post-hoc test was used. Differences were
considered significant for p < .05. Correlation analysis between the
number of GFP1 cells and the extent of demyelination in the fasciculus
gracilis area was performed by applying the Pearson’s correlation test.
3 | RESULTS
3.1 | In mouse spinal cord, GPR17 is expressed in cells
of the oligodendroglial lineage
As a first step, we characterized the expression pattern of GPR17 in
spinal cord of adult mice. The GPR17 receptor protein was present in
a relatively high number of cells throughout the whole spinal cord
(Figure 1a), where it clearly decorated oligodendroglial cells, as con-
firmed by co-localization with the typical oligodendroglial transcription
factor OLIG2 (Figure 1b,b0). In particular, GPR17 is expressed in early
OPCs with a bipolar phenotype positive for NG2, but also in maturing
oligodendrocyte precursors positive for CC1 (Figure 1c,c0 ,d,d0). No co-
localization was found with either microglial, astrocytic or neuronal
markers, like IBA1, GFAP, and MAP2, respectively (Figure 1e–g). Thus,
we confirmed that also in spinal cord, as previously shown for brain
(Lecca et al., 2008; Boda et al., 2011; Ceruti et al., 2011), GPR17 is spe-
cifically expressed in a subset of oligodendrocyte precursors at inter-
mediate stages of differentiation.
3.2 | GPR17-expressing OPCs respond to EAE
induction but do not reach terminal maturation
To unveil disease related changes of GPR17 mRNA and protein, we
induced EAE in mice and followed disease development at 10, 20, and
40 days post immunization (DPI). As expected, during EAE develop-
ment, we observed a progressive loss of cells belonging to the oligo-
dendrocyte lineage. This initial general analysis showed a trend to
decrease in the number of OLIG21 cells, many of which were also posi-
tive for GPR17 that indeed decorated heterogeneous subsets of imma-
ture oligodendrocytes (Figure 2a). For our subsequent studies, we
focused on the acute phase, when spinal cord inflammation is high,
clinical symptoms severe and the highest decrease in OLIG2 is accom-
panied by a strong reduction in the number of the GPR171 cell pool.
Mice were sacrificed 20 days after EAE induction, spinal cords were
explanted and analyzed by both qRT-PCR and immunohistochemistry
in both WM and GM.
At this time point, we observed a significant decrease of CC11-
mature oligodendrocytes (Figure 2b) in the WM (but not in the GM),
whereas the number of early NG21 OPCs was almost unaltered (Figure
2c). However, the subset of the GPR171/NG21 cells (i.e., intermediate
precursors), was markedly increased, indicating that these cells specifi-
cally respond to injury. Of note, this increase was evident only in the
WM, but not in the GM (Figure 3a,b) that is relatively spared in this
model, confirming this behavior be restricted to the regions where demy-
elination occurs. Despite this increase, the number of more advanced
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FIGURE 1 Confocal images of control mouse spinal cord immunolabeled for GPR17 and other markers. (a) Distribution of GPR171-cells (in
red) in the spinal cord of an adult mouse. Cell nuclei were labeled with Hoechst 33258 (in blue). GPR171-cells expressed the
oligodendroglial marker OLIG2 (b and inset b0). GPR17 staining showed co-localization with both the early OPC marker NG2 (c and inset c0)
and the more mature marker CC1 (d and inset d0). No GPR17 positivity was found in microglia (IBA11 cells), astrocytes (GFAP1 cells) and
neurons (MAP21 cells) (e, f, and g). Micrographs were taken at the confocal microscope (Zeiss LSM 510 Meta). Scale bars: 200 mm (a),
50 mm (b–g), 20 mm (b0 , c0, and d0) [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 2 Oligodendrocyte alterations during EAE. (a) Animals were analyzed on 10, 20, and 40-day post immunization (DPI). We reported
oligodendrocyte (OLIG21-cells) loss at each time-point as expected in this disease; most of these cells were GPR17-expressing OPCs and
immature oligodendrocytes; in particular, upon acute EAE (20 DPI) there was a significant decrease of CC11 mature oligodendrocytes (b).
At this time, the NG21 OPCs were almost the same in both white (WM) and gray (GM) matter (c). Unpaired two-tailed Student’s t test;
**p < .01 compared with control from two independent experiments
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GPR171/CC11 cells was apparently unchanged in both WM and GM
(Figure 3c,d) suggesting that these cells cannot proceed any further.
Real-time PCR analysis showed that Gpr17 mRNA was almost
doubled in EAE spinal cord compared with control (Figure 3e), along
with two inflammatory cytokines (i.e., Il-1b and Tgf-b), which confirmed
the presence of strong acute inflammation (Figure 3f). Increased Gpr17
gene expression was also confirmed by in situ hybridization analysis
showing Gpr17-expressing cells accumulating at the borders of EAE
infiltration sites (Figure 3g). Immunofluorescence analysis confirmed
that increased levels of Gpr17 mRNAs are followed by increased recep-
tor protein synthesis, as shown by the large presence of cells express-
ing the GPR17 protein at demyelinating foci, where inflammatory cells
expressing the typical microglia/monocyte marker IBA1 were also
found (Figure 3h). Globally, these data suggest that, (i) as expected,
EAE induction greatly affects oligodendrocytes, and that (ii) the subset
of GPR171 OPCs rapidly reacts to the demyelinating insult, likely to
replace dying cells.
Then, to assess if these reacting cells are indeed able to undergo
terminal differentiation at inflammatory sites and generate new myeli-
nating oligodendrocytes, we took advantage of the first transgenic
inducible reporter GPR17-iCreERT2xCAG-eGFP mouse line (Figure 4a).
Thanks to the activity of a Cre recombinase, in these mice, upon
tamoxifen administration, the cells that are expressing GPR17 at that
moment are permanently labeled by the green fluorescent protein GFP
(GFP1 cells; Figure 4a; Vigano et al., 2016) thus allowing us to trace
their destiny throughout animal’s life. Since GPR17 is only transiently
expressed by OPCs and is no longer present in mature myelinating oli-
godendrocytes, use of this transgenic mouse line is the only possible
means to follow in vivo the final destiny of the GPR171 pool of OPCs,
even when these cells have already physiologically down-regulated the
receptor.
First, to confirm successful transgene recombination and the iden-
tity of recombined cells, we analyzed spinal cord sections in healthy
GPR17-iCreERT2xCAG-eGFP mice. Virtually all the recombinant GFP1
cells remained within the oligodendrocyte lineage, as nearly all of them
were OLIG21 (Figure 4b,c). Many GFP1 cells were also positive for
GPR17 (Figure 4d) and NG2 (Figure 4e) suggesting that, 5 weeks after
tamoxifen treatment, they were still at a precursor stage. Although
they were not abundant, several GFP1/GSTp1 cells were also detected
(Figure 4f), suggesting that a fraction of the initial GPR171 OPCs
indeed underwent maturation. Vice versa, no co-localization of GFP1
cells was found with markers of microglia, neurons, astrocytes (IBA1,
NEUN, and GFAP, respectively; Figure 4g–i), as already demonstrated
in the brain of these mice (Vigano et al., 2016).
Then, we determined the fate of recombined GFP1 cells after
EAE using the same protocol described above. To avoid any pharmaco-
logical interference with disease onset (Tripathi, Rivers, Young,
Jamen, & Richardson, 2010), tamoxifen was administered to adult
FIGURE 3 Characterization of GPR17 subpopulations and changes of GPR17 expression in acute EAE in spinal cord. Animals were analyzed
21 days after immunization (acute EAE). Upon acute phase, there was a significant increase of GPR171/NG21 cells (OPCs), only in the white
matter (WM; a and b); conversely, the number of GPR171/CC11 cells (immature oligodendrocytes) was apparently unchanged in both WM and
GM (c, d). Data are the mean 6 SEM of cervical, thoracic and lumbar sections; (CTL n 5 3, EAE n 5 5). Unpaired two-tailed Student’s t test;
****p < .0001 compared with control from two independent experiments. (e) By means of real-time PCR, a significant up-regulation of GPR17
was found in spinal cord of mice after acute EAE compared with controls and this correlated with the increased expression of inflammatory
cytokines (f). Histograms show the fold change value 6 SEM compared with control set to 1. Two-tailed Mann-Whitney student t test, *p  .05,
**p < .01 from three independent experiments. (g) GPR17 up-regulation was also confirmed by means of in situ hybridization at the lesion site
(black arrows) indicate cells with increased levels of Gpr17 mRNA. Scale bar 100 lm. (h) A local up-regulation of GPR171 cells (white arrows)
was observed after EAE induction in the same area where inflammatory cells infiltrate the tissue (characterized by a high number of nuclei, in
blue), bordered by IBA11 activated microglial cells. Scale bar 50 lm [Color figure can be viewed at wileyonlinelibrary.com]
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GPR17-iCreERT2xCAG-eGFP transgenic mice 2 weeks before EAE
induction (protocol in Figure 5a). Analysis of clinical scores confirmed
the expected disease development (Figure 5b), suggesting that these
mice react to EAE induction as wild-type animals, and that tamoxifen
does not influence EAE susceptibility. Spinal cord sections from these
mice were analyzed by immunofluorescence at day 21 after
FIGURE 4 Identity of recombinant cells in the adult spinal cord. (a) Schematic representation of the transgenic alleles in GPR17-iCreERT2xCAG-
eGFP mice showing tamoxifen-responsive recombination of the CAG-GFP allele to induce GFP in cells expressing GPR17. (b and c) Quantification of
OLIG21 cells among GFP1 cells in the spinal cord reveals that nearly all recombined cells belong to the oligodendroglial lineage. Many GFP1 cells
were also found positive for GPR17 (d) and the NG2 marker (e). Although they were not abundant, we detect the presence of some GFP1GST1 cells
(f). Vice versa, GFP1 cells are not positive for the markers of microglia, IBA1 (g), neurons, NEUN (h) and astrocytes, GFAP (i). Images were taken at the
confocal microscope (Zeiss LSM 510 Meta). Scale bar: 10 mm (c and f), 5 mm (c0), 50 mm (d–i) [Color figure can be viewed at wileyonlinelibrary.com]
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immunization. Quantification of the number of GFP1 cells in whole spi-
nal cord sections revealed significant increases in the WM, and, to a
lesser extent, in the GM of EAE mice compared with controls (Figure
5c). A more detailed analysis showed that, after EAE, in WM the num-
ber of the GFP1 cells that also expressed NG2 (i.e., cells that were still
at a precursor stage) significantly increased, whereas the number of
more mature GFP1 cells expressing the more advanced marker GSTp,
did not change (Figure 5d,e). Conversely, in GM, where demyelination
was not evident, the number of GFP1/NG21 cells did not change, but
the number of GFP1/GSTp1 cells raised significantly (Figure 5f,g).
FIGURE 5 Reaction and fate of recombined cells in the spinal cord of GPR17-iCreERT2xCAG-eGFP mice after acute EAE. (a) Mice received
tamoxifen by oral gavage three times (every other day), starting 14 days before EAE induction, and were analyzed in the EAE acute phase
(day 21 after immunization). (b) Clinical scores of mice during acute EAE. Error bars represent mean of CS 6 SEM. (c) Quantification of the
number of GFP1 cells in whole spinal cord white (WM) and grey (GM) matter of EAE mice compared with controls. Quantification of GFP1/
NG21- and GFP1/GSTp1- cells in both WM (d and e) and GM (f and g) in spinal cord of EAE mice. Data are the mean 6 SEM; (CTL n 5 2,
EAE n 5 5). Unpaired two-tailed Student’s t test; #p < .01, *p < .05, ***p < .001 compared with control. (h and i). Representative micro-
graphs showing myelination (fluoromyelin red staining), GFP1 cells (green fluorescence) and nuclei (in blue) in the area of the fasciculus gra-
cilis (FG) in control and EAE mice. The accumulation of nuclei in the FG corresponds to infiltrating cells. A decrease in myelination level
coupled to a strong increase in the number of GFP1 cells was found in the area. Scale bars: 100 mm. The distribution graphs show the per-
centage of myelination (j) and the number of GFP1 cell/mm2 (k) in the fasciculus gracilis of the spinal cord in EAE mice compared with con-
trols. Data are the mean 6 SEM of cervical, thoracic and lumbar sections; (CTL n 5 15, EAE n 5 41). Unpaired two-tailed Student’s t test;
****p < .0001. (l) The number of GFP1 cells was correlated to the extent of demyelination for different FG sections of EAE mice by per-
forming a Pearson’s correlation test (r 5 .585; p value 5 .0001). The analysis showed a strong association between the two variables [Color
figure can be viewed at wileyonlinelibrary.com]
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Globally, these data suggest that the population of GFP1 cells is reacting
in the WM, mostly by expanding the pool of precursors. However, this
expansion is not followed by cell maturation, suggesting that the differ-
entiating abilities of these cells are impaired. Instead, in the GM, where
less inflammation and no significant expansion of the GFP1 cells were
found, a fraction of cells that expressed GPR17 at the time of tamoxifen
administration underwent maturation, and acquired the myelin marker
GSTp. We postulate this different behavior of GFP1 cells in the GM
compared with the WM be due to different extrinsic determinants in
these two spinal cord regions, and that, in the WM, despite the local
expansion of the NG21 OPC pool, higher demyelination-associated
inflammation contributes to impaired OPC maturation. To corroborate
the potential link between GFP1 cell response and the extent of demye-
lination, we focused our subsequent analysis on spinal cord fasciculus
gracilis, an area in which most EAE sections invariably show marked
demyelination and infiltrating cells (Massella et al., 2012). Representative
images showed a marked increase of GFP1 cells in section from EAE
compared with control mice; these cells were clearly found in the WM
close to the central demyelinated area identified by lack of fluoromyelin
red staining (Figure 5h,i). We then quantified the demyelination degree
in 41 fasciculus gracilis of EAE mice compared with 15 control sections.
By setting to 100% the fluoromyelin signal of controls, a mean demyelin-
ation degree of 24.6% was detected in EAE mice (Figure 5j) In the same
area, the density of GFP1 cells was increased to 189.8% (Figure 5k) in
the EAE compared with control group set to 100%. Correlation analysis
confirmed a strong association between the number of GFP1 cells and
the extent of demyelination (Figure 5l).
3.3 | GPR17-expressing OPCs respond to toxic
damage by expanding their pool and contributing
to remyelination in the cuprizone model
In the EAE model, both inflammation and demyelination are very strong
due to T-cell activation and inflammatory infiltrates, and remyelination
FIGURE 6 Reaction of GPR171 OPCs in the corpus callosum of cuprizone fed mice. (a) Mice received a 2% cuprizone-supplemented diet
for up to 5 weeks (W) to induce demyelination and were then switched to normal diet to allow spontaneous remyelination. Expression pro-
file of Mbp (b), Gpr17 (c), and IL-1b (d) genes in the corpus callosum during demyelination (1, 3, and 5 weeks of cuprizone diet indicated as
W0, W1, W3, and W5) and during the remyelination phase after cuprizone withdrawal (7 weeks, 7W). Mbp expression followed the typical
already published pattern, with a marked decrease at W1–W5, followed by recovery at W7; in the case of Gpr17, an initial decrease was
followed by increased expression at later phases of demyelination (3W and 5W). Gpr17 up-regulation persisted also after cuprizone with-
drawal (W7). As expected, IL-1b expression increased overtime, peaking at W5. Data are the mean 6 SEM of four animals for each time-
point; one-way ANOVA with Tukey’s multiple comparison post test; *p < .05, **p < .01, ***p < .001 compared with W0. (e–i) Qualitative
immunostaining showing GPR17 expression (in red) during demyelination and remyelination phases in corpus callosum (highlighted by the
white dotted lines). The red inset in the brain’s drawing refers to the area where the IHC analysis reported in e–i was performed. Scale
bar 5 200 mm [Color figure can be viewed at wileyonlinelibrary.com]
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occurs to a limited extent. Thus, to evaluate the importance of immune
activation and inflammation in the changes of GPR171 OPCs, we took
advantage of the cuprizone model, a toxic-induced demyelination para-
digm in which immune system is not involved, inflammation is tran-
sient, and the kinetics of both demyelination and the subsequent
remyelination phase are clearly defined (Supporting Information
Figure S1). To this purpose, wild-type mice received a cuprizone-
supplemented diet for 5 weeks to cause demyelination and were then
switched to normal diet for further 3 weeks to allow spontaneous
remyelination (Figure 6a). As expected, in corpus callosum expression
of the myelin gene Mbp showed typical time-dependent changes con-
sisting in an immediate decrease already evident after 1 week (W1), fol-
lowed by a rapid recovery after cuprizone withdrawal (Figure 6b).
Gpr17 expression showed a trend to decrease at W1 followed by rapid
and significant upregulation peaking at W5 and returning toward con-
trol levels after cuprizone withdrawal (Figure 6c), with kinetics similar
to those of the proinflammatory cytokine IL-1b (Figure 6d).
The time dependent changes of GPR17 were also confirmed by
IHC data. After an initial decrease, due to cuprizone-induced cell loss
(W1; Figure 6e,f), during the demyelination phase we observed a strong
accumulation of cells expressing the GPR17 receptor protein in corpus
callosum (W3–5; Figure 6g,h), suggesting that OPCs were responding
to damage and started to differentiate.
In line with what observed for the Gpr17 gene (Figure 6c), during
the remyelination phase, the number of GPR171 cells in corpus cal-
losum peaked at W5 and then returned to basal levels at W8
(Figure 6i).
Then, to assess whether, in this demyelinating model, GPR171
reacting cells undergo differentiation or stay blocked at immature
stages as in the EAE model, we fed GPR17-iCreERT2xCAG-eGFP mice
with cuprizone, and, at W3, induced GFP expression with tamoxifen
(Figure 7a). This specific timing of tamoxifen administration was chosen
to properly monitor the final fate of the OPCs that were expressing
GPR17 at the beginning of the OPC proliferation wave (Gudi et al.,
2014). At W8, mice were sacrificed and the maturation stage of the
reacting GPR171 cells was assessed by double labeling for both GFP
and, either NG2 (a marker of oligodendrocyte precursors) or GSTp (a
marker of mature oligodendrocytes). Similarly to EAE, a marked
increase in the number of GFP1 cells (Figure 7b–d) was found in the
corpus callosum of cuprizone fed mice compared with controls, sug-
gesting a damage-induced expansion of the GPR171 pool of cells at
W3. In this model, a role for OPCs originating from the subventricular
zone (SVZ) has been also suggested (Xing et al., 2014). However, our
staining showed a very low induction of GPR17 in this area (data not
shown), suggesting a minor involvement of SVZ-derived GFP1 cells in
the remyelination process.
FIGURE 7 The pool of expanded GPR171 OPCs undergoes terminal maturation in response to cuprizone-induced demyelination. (a)
GPR17-iCreERT2xCAG-eGFP mice received a 0.2% cuprizone (CPZ)-supplemented diet for up to 5 weeks (W) to induce demyelination and
were then switched to normal diet to allow spontaneous remyelination. Tamoxifen induction was performed at 3W after beginning the
cuprizone diet. Analyses were performed at the end of the experimental protocol (8W). (b and c) Qualitative immunostaining showing GFP
expression (in green) in corpus callosum (cc) merged with Hoechst 33258 (in blue) to label cell nuclei. (d and e) Quantification of the number
of GFP1-cells and GSTp1 cells in cc of CPZ fed mice compared with mice receiving standard diet (CTL). (f and g) Quantification of the num-
ber of GFP1/GSTp1 cells and GFP1/NG21 compared with GFP1 cells in cc of CPZ fed mice (n 5 3). Data are the mean 6 SEM. Unpaired
t test; **p < .01, ****p < .0001, ####p < .0001, compared with mice receiving the standard diet (CTL). Scale bar 5 25 mm [Color figure can
be viewed at wileyonlinelibrary.com]
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Although the number of GSTp1 cells was still lower in the corpus
callosum of cuprizone fed mice compared with control (Figure 7e), in
the cuprizone group, a significantly higher number of OPCs stained for
both GSTp and GFP was found (Figure 7f), suggesting that many of the
OPCs expressing GPR17 at W3 had been able to reach terminal matu-
ration after cuprizone withdrawal. Accordingly, at W8, the number of
early GFP1 precursors still expressing NG2 was lower in the cuprizone
group compared with controls (Figure 7g).
Globally, these data suggest that, at variance from EAE, in this
model of demyelination, GPR171 OPCs are able to react to the toxic
damage induced by cuprizone administration by first expanding their
pool and then progressing to terminally differentiated cells, thus effec-
tively participating to remyelination.
4 | DISCUSSION
In recent years, GPR17 has emerged as an important key actor in oligo-
dendrogenesis. Previous studies have shown that, in the brain, GPR17
acts as an intrinsic regulator of this process: indeed, it is necessary to
start OPC differentiation but, after a certain stage, it has to be turned
down to allow oligodendrocyte terminal maturation (Fumagalli et al.,
2015; Fumagalli, Lecca, Coppolino, Parravicini, & Abbracchio, 2017).
These features have led to the proposal that GPR17 represents a new
potential target for remyelination therapies in diseases characterized by
myelin disruption such as multiple sclerosis. Here, for the first time, we
define the differentiation capabilities of GPR171 cells in rodents after
myelin disruption in two different models, the former characterized by
diffused immune response against myelin components and strong
inflammation (the EAE model), and the latter one consisting in local
demyelination induced by a toxic agent (the cuprizone model).
In physiological conditions, only a subset of OPCs (typically 30%–
40%) express GPR17 (Boda et al., 2011; Vigano et al., 2016) in both
brain and spinal cord, suggesting a role in the normal homeostasis and
in oligodendrocyte turnover. Here, we confirm that GPR171 cells are
widespread throughout the whole spinal cord, both in the GM and
WM, showing co-localization with both the early marker NG2 and the
more advanced marker CC1.
As expected, in the EAE model, 21-days after immunization, there
was a general depletion of oligodendrocytes, as shown by a trend to
decrease in OLIG21 and GPR171 cells (Figure 2a) and a statistically sig-
nificant reduction of mature CC11 cells (Figure 2b), suggesting that
mature oligodendrocytes are likely to be more affected by disease
induction. At this stage, the total number of spinal cord NG21 cells was
unaltered in both the GM and WM (Figure 2c). However, double immu-
nofluorescence analysis on these precursors showed that the NG21/
GPR171 subpopulation was increased in the WM but not in the GM,
which was indeed relatively spared (Figure 3a), demonstrating that, (i)
the GPR171/NG21 subset of cells reacts to the insult, and that (ii) this
behavior is restricted to the region where demyelination occurs.
Detailed fate mapping analysis in inducible GPR17-iCreERT2xCAG-
eGFP reporter mice, that allows monitoring the behavior and destiny of
GPR171 cells by tamoxifen-induced GFP labeling, confirmed a strong
increase in the number of GFP1 cells in damaged areas in both demye-
linating models. These results are in line with previous literature data
showing that, after injury, OPCs enhance their pool of progenitors, are
actively recruited at the sites of focal CNS injury, and rapidly migrate
and proliferate to restore their density (Hughes, Kang, Fukaya, & Ber-
gles, 2013). However, we also show that only in the cuprizone model
GFP1 cells do actually differentiate to mature oligodendrocytes con-
tributing to remyelination (Figure 7f). In EAE spinal cord, significant
maturation of GPR171 cells was only observed in the GM (Figure 5g),
which is minimally affected by damage. This is in contrast with litera-
ture data showing that, in general, OPCs maturate more rapidly in the
WM compared with GM (Vigano, Mobius, Gotz, & Dimou, 2013; Vig-
ano et al., 2016), suggesting that, in EAE, specific local extrinsic factors
are responsible for altered OPC behavior. We indeed postulate that, in
the EAE model, the inability of WM GFP1 cells to maturate can be
due, at least in part, to the presence of a strong chronic proinflamma-
tory environment blocking cells at immature stages and preventing
their terminal maturation. To further support this hypothesis,
cuprizone-induced demyelination mainly evolves as a toxic insult with
much less involvement of immune cells leading to less inflammation,
likely resulting in a more permissive local environment for OPC matura-
tion (Gudi et al., 2014).
Of course, we cannot exclude that such differential responses can
also be due, at least in part, to different OPCs intrinsic programs in spi-
nal cord and corpus callosum. Adult OPCs indeed originate from evolu-
tionary distinct populations, and for this reason they keep different
physiological features and capabilities to respond to demyelination for
their whole life (Ornelas et al., 2016).
Consistent with our data, the role of GPR17 in addressing OPCs to
maturation has been recently confirmed. Indeed, in line with the
already postulated heterogeneity of oligodendroglial precursors (Vigano
& Dimou 2016) a recent transcriptome analysis identified 12 distinct
populations as a continuum in the differentiation process suggesting
that the term “OPCs” represents a strong approximation of the actual
genic and functional diversity of these cells. Of interest, GPR17 was
identified in three of these populations defined as “differentiation com-
mitted precursors” (Marques et al., 2016). This confirms that our
GPR17 reporter mouse line is a useful tool to fate-map a specific sub-
population of intermediate precursors committed to maturation, rather
than simply highlighting a general “prototypic” early response of NG2-
cells.
Interestingly, the lack of OPC terminal maturation in EAE tissues is
also accompanied by persistent GPR17 overexpression. As already
mentioned, while GPR17 is needed to start differentiation, its chronic
overexpression due to impaired physiological downregulation has been
associated to OPC blockade and impaired remyelination (Fumagalli
et al., 2015; Ou et al., 2016). Besides EAE (the present study), several
other distinct models of brain disease, including stroke, trauma, Alzhei-
mer’s (Fumagalli et al., 2016) have been associated to persistent
GPR17 upregulation and impaired progression along the oligodendro-
cyte lineage, eventually resulting in dysfunctional repair. Importantly,
GPR17 has been shown to “promiscuously” respond to several differ-
ent proinflammatory ligands accumulating at injury sites (Sensi et al.,
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2014; Parravicini et al., 2016), not only uracil nucleotides and cysteinyl-
leukotrienes (Ciana et al., 2006), but also oxysterols and CXCL12 (Par-
ravicini et al., 2016), one of the most prominent chemokines in the
lesions of multiple sclerosis patients (Calderon et al., 2006). In a permis-
sive environment, these inflammatory stimuli could initially contribute
to promotion of remyelination through GPR17 stimulation, in line with
literature data proposing that acute inflammation triggers remyelination
(Foote & Blakemore 2005). However, when inflammation becomes
stronger and chronic (as it occurs when EAE is overtly symptomatic),
this beneficial effect is turned into a detrimental condition (Marchetti &
Abbracchio 2005) that worsens rather than favor, remyelination. In line
with this hypothesis, the strong inflammatory milieu associated to the
degenerative conditions mentioned above is accompanied by GPR17
upregulation (Fumagalli et al., 2015), which prevents terminal OPC mat-
uration and remyelination.
Based on the above evidence, on the strikingly different contribu-
tion of inflammation to EAE- and cuprizone-induced demyelination
(Denic et al., 2011; Gudi et al., 2014), and based on the different capa-
bility of GPR171 OPCs to undergo maturation in these two rodent
models (the present results), we speculate that the proinflammatory
local environment associated to EAE induction is responsible for persis-
tent GPR17 overexpression in OPCs, leading to their blockade at imma-
ture stages.
Our data open new directions to treat demyelination in neuroin-
flammatory diseases, such as multiple sclerosis, in which inappropriate
resolution of acute inflammation leads to its chronicization. They also
suggest that remyelinating approaches should be combined to thera-
pies controlling chronic inflammation, in order to achieve effective
myelin repair and retard neurodegeneration.
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